CoChat

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine

Open access
Tan, Yee Sun, Sansanaphongpricha, Kanokwan, Xie, Yuying, Donnelly, Christopher R., Luo, Xiaobo, Heath, Blake R., Zhao, Xinyi, Bellile, Emily, Hu, Hongxiang, Chen, Hongwei, Polverini, Peter J., Chen, Qianming, Young, Simon, Carey, Thomas E., Nör, Jacques E., Ferris, Robert L., Wolf, Gregory T., Sun, Duxin, Lei, Yu L. · 2018 · Clinical Cancer Research
Cited by 150

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Purpose: The response rates of Head and Neck Squamous Cell Carcinoma (HNSCC) to checkpoint blockade are below 20%. We aim to develop a mechanism-based vaccine to prevent HNSCC immune escape. Experimental Design: We performed RNA-Seq of sensitive and resistant HNSCC cells to discover central pathways promoting resistance to immune killing. Using biochemistry, animal models, HNSCC microarray, and immune cell deconvolution, we assessed the role of SOX2 in inhibiting STING-type I interferon (IFN-I) signaling-mediated antitumor immunity. To bypass SOX2-potentiated STING suppression, we engineered a novel tumor antigen–targeted nanosatellite vehicle to enhance the efficacy of STING agonist and sensitize SOX2-expressing HNSCC to checkpoint blockade. Results: The DNA-sensing defense response is the most suppressed pathway in immune-resistant HNSCC cells. We identified SOX2 as a novel inhibitor of STING. SOX2 facilitates autophagy-dependent degradation of STING and inhibits IFN-I signaling. SOX2 potentiates an immunosuppressive microenvironment and promotes HNSCC growth in vivo in an IFN-I-dependent fashion. Our unique nanosatellite vehicle significantly enhances the efficacy of STING agonist. We show that the E6/E7–targeted nanosatellite vaccine expands the tumor-specific CD8+ T cells by over 12-fold in the tumor microenvironment and reduces tumor burden. A combination of nanosatellite vaccine with anti-PD-L1 significantly expands tumor-specific CTLs and limits the populations expressing markers for exhaustion, resulting in more effective tumor control and improved survival. Conclusions: SOX2 dampens the immunogenicity of HNSCC by targeting the STING pathway for degradation. The nanosatellite vaccine offers a novel and effective approach to enhance the adjuvant potential of STING agonist and break cancer tolerance to immunotherapy. Clin Cancer Res; 24(17); 4242–55. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2807

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 150

Metadata

Authors
Tan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E., Hu, H., Chen, H., Polverini, P. J., Chen, Q., Young, S., Carey, T. E., Nör, J. E., Ferris, R. L., Wolf, G. T., Sun, D., & Lei, Y. L.
Venue
Clinical Cancer Research
Published
2018-09-01
Volume
24
Issue
17
Pages
4242-4255
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2804407252
Cited by
150
References
11
FWCI
5.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2807
The paper
Tan, Y. S., Sansanaphongpricha, K., Xie, Y., Donnelly, C. R., Luo, X., Heath, B. R., Zhao, X., Bellile, E., Hu, H., Chen, H., Polverini, P. J., Chen, Q., Young, S., Carey, T. E., Nör, J. E., Ferris, R. L., Wolf, G. T., Sun, D., & Lei, Y. L. (2018). Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2807

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.